
|Articles|August 28, 2014
- Head and Neck Cancers (Issue 1)
- Volume 1
- Issue 1
Results of the SELECT Trial in Thyroid Cancer
Author(s)Martin Schlumberger, MD
Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Advertisement
Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Learn more about targeted agents and radioactive iodine resistance > >
Articles in this issue
over 11 years ago
Unmet Needs in the Treatment of Thyroid Cancerover 11 years ago
Immunotherapy in Head and Neck Cancersover 11 years ago
Molecular Markers Emerge in the Diagnosis of Thyroid Cancerover 11 years ago
Update on Targeted Therapies in Head and Neck CancersAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















